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Abstract
Background and methods: In cystic fibrosis, growth and lung function have been identified as prognostic markers of both
severity of pulmonary disease and survival. Cross-sectional studies in patients with cystic fibrosis (CF) including all genotypes
have shown that in prepubertal patients with lifetime continuous care within a specialised CF centre, growth can normalise. No
corresponding improvement in lung function has been found. We used a longitudinal design to determine whether normalisation
of growth could be found in the genetic subgroup of prepubertal children with CF with the homozygous DF508 mutation, which
is one of the known severe mutations. Methods: Data of all children born after 1980 with the homozygous DF508 mutation,
diagnosed in early childhood at the specialised centre of the Children’s Hospital of Berne were systematically assessed up to the
age of 11 years and retrospectively analysed. Follow-up data of height, weight and BMI were compared to the Swiss reference
population using z-scores. The correlations between lung function parameters (FEV1, MEF50, VC) and age, as well as lung
function parameters and growth indices, were calculated. Additionally, the same correlations were examined in a cohort with the
same mutation born 10 years earlier. Results: In the study, cohort growth (height, weight and BMI) was significantly below that
of the normal Swiss population. A significant decline of lung function with age was also found, however, no association between
lung function and growth could be seen. Compared to an earlier cohort, an improved growth over the last decade could be shown
but no improvement on lung function could be detected. Lung function varied widely in both groups. Conclusion: In contrast to
sequential cross-sectional studies of children with CF, the present longitudinal study of children with homozygous for the DF508
mutation failed to confirm normalisation of growth over time. However, compared to the data of children born in the previous
decade, improved growth was observed.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The clinical outcome of children with cystic fibrosis
has improved over the last decades. Many different
defects in the CF transmembrane conductance regulator
(CFTR) gene have been identified and result mainly in
a progressive lung disease, pancreatic dysfunction, male
infertility and other abnormalities. The severity of dis-
ease and the loss of organ function vary widely. The
clinical heterogeneity of CF is remarkable, particularly
in respect to age at onset and severity of lung disease
in different age groups.
Growth and nutritional problems in patients with CF
have been discussed for years. In a longitudinal study
of secular changes from 1960 to 1990 of anthropometric
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data in Danish CF population, a significant increase in
body mass index (BMI) has been shown w1x. Another
Danish study w2x of growth and survival has revealed
normal height in all age groups and normal weight and
BMI in prepubertal patients, but values below normal
weight in adolescents and adults. An Australian group
also found improved growth in comparison to earlier
studies w3x. Lifetime continuous care in a specialised
centre with changes in treatment and changes in dietary
recommendations were cited as most important contrib-
utory factors in all these studies w1–3x.
Kraemer et al. w4x showed that relative underweight
correlated closely with poor survival. Relatively under-
weight and BMI have been identified as prognostic
markers of both severity of pulmonary disease and
survival w2,4–6x. Nir et al. w2x assumed that patients
with uncontrolled lower respiratory tract infections are
those with the greatest loss of weight.
77B.M. Keller et al. / Journal of Cystic Fibrosis 2 (2003) 76–83
The identification of the most common DF508 muta-
tion and an increasing number of other mutations in
1989 has promoted extensive research into the associa-
tion between genotype and phenotype, which has con-
tributed to understand some of the mechanisms of the
wide clinical variability in CF w7–12x. Patients with the
DF508 homozygous mutation have been described in
several reports as those with severe disease w7,9,13,14x.
Characteristics of the severe phenotype are defined by:
early age at diagnosis; pancreatic insufficiency; poor
nutritional status; high incidence of meconium ileus;
and high sweat chloride levels w14x. A close association
between the DF508 mutation and pancreatic insufficien-
cy has been described w7x. The described improvement
in growth over the last decades was assessed in all
mentioned studies on large CF cohorts but without a
differentiation of genotypes. Thus, the question, whether
the normalised prepubertal growth can also be observed
in this most frequent and known as severe mutation, is
open.
In this retrospective study, we looked at: (1) longitu-
dinal values of growth (body weight, body height and
BMI) of CF children with the homozygous DF508
mutation, and compared this group of patients to the
growth of the normal population; (2) the association
between lung function and age and the association
between lung function and growth; and (3) longitudinal
growth and lung function data of CF children compared
to CF children born 10 years earlier with the same
mutation.
We hypothesised that values of weight and height are
below those of the normal population despite of the
normalised growth in prepubertal children with CF
described in literature, due to the fact that the homozy-
gous DF508 mutation is one of the more severe muta-
tions w7,9,13,14x. Furthermore, an association of growth
and lung function, as described in several earlier studies,
was expected. An improvement in growth and lung
function over time was expected in comparison to
children with the same mutation born 10 years earlier.
2. Materials and methods
The data of 35 children with cystic fibrosis born from
1982 to 1996, homozygous for the DF508 mutation,
regularly followed at the CF outpatient clinics of the
Children’s Hospital of Berne, were included in this
retrospective analysis. This group will be named group
A: all were native Swiss. The diagnosis was initially
made by typical clinical symptoms andyor family history
of CF confirmed with at least two abnormal sweat tests
(pilocarpin iontophoresis) and genetic confirmation of
DF508 homozygosity. Weight and height were deter-
mined at every visit beginning from the age of 1 year
every 6 months until the age of 2 years, at 5, 8 and 11
years. In addition pulmonary function tests were per-
formed using a whole body plethysmograph (Jaeger
Wurzburg) in those older than 5 years. Forced expiratory¨
volume in 1 s (FEV1), maximal expiratory flow at 50%
of vital capacity (MEF50) and vital capacity (VC) were
measured and values expressed in percentage predicted
of normal values for sex and height w15,16x.
BMI was calculated as weightyheight and expressed2
as standard deviation score (z-score). Z-scores for height
and weight were calculated in the same manner. As a
reference population, data of the first Zurich longitudinal
study of growth and development w17x were taken.
Unpublished data of the second Zurich longitudinal
study have not shown significant changes in physical
growth, so it has been recommended by the Zurich
research team to work with the published data, which
describe growth from birth to adulthood between 1954
and 1976.
The second group, named group B, included: 40
children born 1968 to 1980 with CF, identified as
homozygous DF508 mutation, who were also regularly
followed at the CF outpatient clinics of the Children’s
Hospital of Berne. All were native Swiss. Growth and
lung function data were retrieved from the medical notes
at the age of 2, 5, 8 and 11 years.
2.1. Statistics
Data were analysed for one point in time, using GLM
(General Linear Model) of SYSTAT 9 (SPSS Inc.)
Linear regression was analysed using ANOVA. Statisti-
cal comparisons between two groups were performed
using the Student’s t-test for normally distributed vari-
ables. The z-scores for weight, height and BMI were
compared with the normal population using a z-test
(one-tailed). In all cases, a P-0.05 was considered
statistically significant.
3. Results
Age at diagnosis in group A was 6.32"6.06 months
(mean"S.D.), with a significant difference Ps0.02 to
group B 13.9"18.7 month (mean"S.D.). Group B
included children, who survived at least until 1989 and
could be genetically identified.
Table 1 shows further characteristics of the study
populations.
Children with the homozygous DF508 mutation in
group A had significantly lower mean z-scores for
height, weight and BMI at any age than the normal
population (Table 2). Mean weight and height z-scores
of the patients aged 1 and 1.5 years were lower than
later on in life (mean height z-score value at 1.5 yearss
y1.27, confidence interval (CI) y1.71 toy0.83; mean
height z-score value at 5 yearssy0.39, CI y0.78 to
0.001). The follow-up of mean z-score value of weight
and height at different time point after diagnosis showed
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Table 1
Characteristics of the study population
Number of patients (FyM) ns35 (17y18)
Group A, born 1982–1996
Age at diagnosis mean"S.D., median 6.32"6.06, 4.41 months
(range) (0–28 months)
Meconium ileus ns9 (25.7%)
Pancreatic insufficiency ns35 (100%)
Death (FyM) in observation period ns2 (1y1), (5.7%)
Age at death (FyM) 11.25y12.67 years
Group B, born 1968–1980
Number of patients (FyM) ns40 (18y22)
Age at diagnosis mean"S.D., median 13.9"18.7, 6.05 months
(range) (0–78 month)
Meconium ileus ns8 (20%)
Pancreatic insufficiency ns40 (100%)
Death (FyM) in observation period ns1 (0y1), (4%)
Age at death 8.8 years
Death in observation period in CF 97y267, (34.5%)
patients, not genetically identified
Table 2
Comparison of mean height, weight and BMI z-scores of the cystic fibrosis group A with the normal population
Age N Height Weight BMI
(years)
z-score 95% CI P value z-score 95% CI P value z-score 95% CI P value
(mean) (mean) (mean)
1 34 y1.1 y1.5 to y0.7 -0.001 y1.1 y1.5 to y0.8 -0.001 y0.5 y0.9 to y0.1 0.005
1.5 32 y1.3 y1.7 to y0.8 -0.001 y0.9 y1.3 to y0.7 -0.001 y0.6 y0.9 to y0.2 0.002
2 31 y0.5 y0.8 to y0.1 0.007 y0.6 y0.93 to y0.2 0.001 y0.5 y0.9 to y0.1 0.004
5 27 y0.4 y0.8 to 0.0 0.028 y0.6 y1.03 to y0.1 0.008 y0.5 y0.9 to y0.0 0.012
8 17 y0.2 y0.8 to 0.4 0.251 y0.66 y1.13 to y0.0 0.012 y0.8 y1.3 to y0.3 0.001
11 9 y0.7 y1.4 to y0.0 0.028 y0.7 y1.3 to y0.2 0.003 y0.9 y1.3 to y0.6 -0.001
that differences to the normal population decreased but
statistical significance was reached only at time point 4
years after diagnosis.
To show graphically the follow-up in patients of group
A from 1 year to the age of 11 years (mean"2 S.D.),
weight and height data are plotted on percentile charts
for males and females separately in Figs. 1–4 w17x.
Looking at sex-specific outcomes, the following
results for males of group A are found (Figs. 1 and 2):
Fig. 1 shows that mean height in male CF older than
1.5 years followed the mean of the normal male popu-
lation up to 11 years with standard deviations within
the same range. The mean z-scores for height were not
significantly lower compared to the normal population.
Z-score values for height were significantly lower only
at age 1 year (mean height z-score value y0.84, CI
y1.48 to y0.2, Ps0.006) and 1.5 years (mean height
z-score value height y0.98, CI y1.55 to y0.41, Ps
0.001).
The mean weight of the CF males was lower than the
mean weight of the normal males (Fig. 2) and signifi-
cantly lower z-score values for weight at the age 1, 1.5,
2 and 8 years compared to the normal population were
found. Calculating BMI z-scores and putting these in
relation to the normal population, at every age a signif-
icant difference could be found. Mean BMI z-scores
values between y0.5 and y0.9 standard deviations
below zero were found.
For females of group A, data are different (Figs. 3
and 4): mean height for CF females was below the
mean of the normal female population and standard
deviations were similar to the normal female population
(Fig. 3). This difference could be documented from
infancy to the age of 11 years. The pattern for female
weight (Fig. 4) followed that of male patients, but the
difference to the mean of normal population was increas-
ing with age and was more pronounced. Up to the age
of 5 years, female weight and height z-scores were
significantly lower than the normal population. At the
age of 8 years, there was no significant difference to
the normal population in height (95% CI, y1.85 to
0.55, Ps0.12) or in weight (95% CI, y1.94 to 0.32,
Ps0.07). The z-scores for BMI of females were in a
normal range. The mean BMI z-scores with 95% CI
show values between y0.3 and y0.7 standard devia-
tions below zero.
Fig. 5 shows the comparison of weight values of the
group A (born 1982–1996) with group B (born 10
years earlier). Mean z-score values of the earlier born
group B were lower than in group A. But only at age 8
years the difference in height and weight reached sig-
nificance (Ps0.016 for heighty0.046 for weight). At
the age of 2 and 5 years BMI z-score values were
significantly lower in group B (Ps0.047 for 2 yearsy
0.0045 for 5 years). The range in every group and age
was large.
In group A, lung function data showed a decline of
respiratory function with age for FEV1 and MEF50.
FEV1 and MEF50 showed a significant linear correla-
tion with age (Fs6.22, Ps0.02 and Fs15.143, P-
0.001); no correlation was found for VC. Linear
correlations between growth parameters, height, weight
and BMI, and lung function indices (FEV1, MEF50,
VC) were not statistically significant. The variability of
z-score values of growth parameters in relation to data
of lung function was large.
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Fig. 1. Follow up of height of male patients group A.
The comparison of lung function values (FEV1, MEF
50, VC) of group A with group B showed no significant
difference between the two groups. At age 11, the
patients in group B (earlier born) had even a higher
value for FEV1 (73.5%"18% predicted) in comparison
to the group A (67.3%"29.5% predicted). In group B,
MEF 50 with the age of 11 years was also higher
(84.4%"27% predicted) than in group A (58%"38.5%
predicted). However, the standard deviation was large
in all age groups.
4. Discussion
The aim of this study was the assessment of growth
of children, suffering from CF, confined to one single
genetic group with the homozygous DF508 mutation.
The data indicate that weight and height of our Swiss
DF508 CF children are mainly below the values of
healthy Swiss children. The mean z-scores for height,
weight and BMI of group A was significantly below
that of the normal Swiss population. A trend to an
improvement in growth variables could be documented
when we compared group A with group B. However,
the improvement did not reach statistical significance.
This may in part be due to the fact that children,
suffering from CF with the homozygous DF508 muta-
tion, who died before 1989 (92y267 in observation
period of group B, 1968–1980) when genetic mutation
screening was begun, were predominantly those with
bad outcome, and therefore the mean values of weight
and height in group B are too high.
The number of patients, the variable length of follow-
up and timing of observation were limiting factors. For
this reason, the statistical methodology of mixed model
analysis w13x, which offers the possibility to precise
estimates of average changes in longitudinal clinical
trials, could not be applied.
A significant inverse association of lung function
(FEV1, MEF50) with age was found. Probably due to
wide variability, the comparison of the two groups A
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Fig. 2. Follow up of weight of male patients group A.
and B showed no statistical difference in lung function.
An association between growth and lung function, as
hypothesised and described in other studies, could not
be seen in our patients.
The evaluation of results for males and females
separately showed a different outcome. The male pop-
ulation had normal z-score values for height at age 2 up
to age 11 years, whereas weight and BMI z-score values
were significantly lower compared to the normal popu-
lation. Females showed differences to the normal pop-
ulation in height and weight up to age of 5 years; at the
age of 8 years the result was not significant (Ps0.121
for heighty0.068 for weight) and at the age of 11 years
the number of children was too small to calculate the
difference. For female BMI z-score values, no statistical
differences to the normal population were found.
Although an improvement in growth in the whole
group and even a normalisation over the last decade
could be documented for height in males older than 1.5
years, the whole group of CF children did not fully
normalise. This is in part in contradiction to other studies
w1–3x, which are based on large CF cohorts, including
all types of mutations and which have demonstrated a
normalisation of height and weight in prepubertal chil-
dren with CF. However, the follow-up of weight and
height in relation to the time point of diagnosis in early
childhood showed the tendency to improve. This impli-
cates that deficits in weight and height can change over
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Fig. 3. Follow up of height of female patients group A.
the years and growth variables can even improve. No
significant difference in growth could be found between
children with and without meconium ileus. The improve-
ment in growth can be attributed to improved treatment
and the lifetime continuous care in a specialised CF
centre. In 1999, Collins et al. w3x showed the positive
influence of specialised care to improve growth, but no
positive influence to lung function. The growth retar-
dation in CF has been thought to be largely preventable,
especially in the prepubertal period w1–3,6x. Despite the
observed tendency of normalised prepubertal growth,
weight and height below normal were found later in
adolescents and adults w2,6x. It has been hypothesised
that the difference is mostly due to the delayed onset of
pubertal growth spurt of CF children.
The relative underweight is accepted to be a prognos-
tic sign of the severity of pulmonary disease and survival
w2,4–6x. BMI, which foretells the proportion of fat in
relation to the whole body mass, was calculated as a
parameter for underweight. In group A, BMI z-scores
of boys and girls together are significantly below the
normal population. In females alone, however, BMI z-
scores were the same as in the normal population. Due
to improvement mainly in weight, the BMI does not
discriminate in the same manner as it has been seen
several years ago.
A significant correlation between decline of lung
function with increasing age was found. This is well
known for the whole CF population, as described in
several studies w7–9,13,18x. In a longitudinal study,
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Fig. 4. Follow up of weight of female patients group A.
Corey et al. w13x assessed the decline of pulmonary
function in patients with CF and showed that all but the
most severely affected patients who died before age of
15, appeared to have normal pulmonary function when
first tested in early childhood. The authors asked for
further longitudinal prospective studies to document the
rate of decline in individual patients, which cannot be
reflected in cross-sectional studies.
Despite the correlation between the decline in lung
function and increasing age, lung function results varied
widely in our observed group. Contributing factors to
this variability are examination of different age groups,
differences in treatment (especially in cross-sectional
studies) and different age at the beginning of treatment.
Health, compliance and motivation during the lung
function test can influence the result.
The assessment of association between lung function
and growth in our study population group A revealed
no significant relation, in contrast to what has been
referred to by some other authors w2,3,5x. Nir et al. w2x
found a strong correlation between BMI and lung
function parameters in all age groups and normal height
and lower body weight in males above 15 and in females
above 10 years of age. Their graphs showed that poor
growth is predominantly present in older patients.
In conclusion, in a longitudinal study of CF patients
with the homozygous DF508 mutation, we showed that
growth is below the normal population from 1 year up
to the age of 11 years. However, compared to the data
of earlier born children we found an improvement in
growth. This could especially be seen in the male group,
who reached normal values for height. Lung function
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Fig. 5. Follow up of mean weight z-score ("1 S.D.) for group A and group B.
results in both groups were similar, no corresponding
improvement could be documented. A decline in lung
function with increasing age was documented, but the
variability was wide. In our children growth and lung
function did not correlate. The value of contributory
factors like age at diagnosis, meconium ileus, compli-
ance and social factors as well as aggravating environ-
mental factors on growth in early childhood and in
puberty will be subject of further research.
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